Literature DB >> 21445635

Targets for therapy in ependymoma.

Nicole A Shonka1.   

Abstract

Ependymomas are among the rarest type of glioma and display significant heterogeneity based on patient age and tumor location. Treatment strategies include surgery and radiation, but the use of chemotherapy remains more controversial. Chemotherapy has been widely utilized in the pediatric population due to more aggressive disease in this cohort, and has become of interest in the adult population as well. Unfortunately, relapses are common, and responses to cytotoxic chemotherapy are often disappointing. As a result, attention has turned to specific targets in the pathogenesis of ependymoma. This paper summarizes the current understanding of promising molecular pathways and targets under study for future application in ependymoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445635     DOI: 10.1007/s11523-011-0170-0

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  54 in total

1.  Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.

Authors:  I Rojas-Marcos; D Calvet; P Janoray; J Y Delattre
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

2.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology.

Authors:  J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo.

Authors:  M H Deininger; M Weller; J Streffer; M Mittelbronn; R Meyermann
Journal:  Acta Neuropathol       Date:  1999-09       Impact factor: 17.088

4.  Intracranial ependymomas: an analysis of prognostic factors and patterns of failure.

Authors:  Arnold C Paulino; B-Chen Wen; John M Buatti; David H Hussey; Weining K Zhen; Nina A Mayr; Arnold H Menezes
Journal:  Am J Clin Oncol       Date:  2002-04       Impact factor: 2.339

5.  alpha(v)beta(3) Integrin in central nervous system tumors.

Authors:  Michael Lim; Samira Guccione; Terri Haddix; Leroy Sims; Samuel Cheshier; Pauline Chu; Hannes Vogel; Griffith Harsh
Journal:  Hum Pathol       Date:  2005-06       Impact factor: 3.466

6.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C.

Authors:  W T Couldwell; J P Antel; V W Yong
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

8.  Recurrent spinal ependymoma showing partial remission under Imatimib.

Authors:  N Fakhrai; P Neophytou; K Dieckmann; A Nemeth; D Prayer; J Hainfellner; C Marosi
Journal:  Acta Neurochir (Wien)       Date:  2004-09-13       Impact factor: 2.216

9.  Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study.

Authors:  Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin
Journal:  Lancet Oncol       Date:  2007-08       Impact factor: 41.316

10.  Cancers in the first-degree relatives of children with brain tumours.

Authors:  K Hemminki; X Li; P Vaittinen; C Dong
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

View more
  2 in total

1.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.

Authors:  Daniela Meco; Tiziana Servidei; Giuseppe Lamorte; Elena Binda; Vincenzo Arena; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

2.  Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Authors:  Valérie Dutoit; Denis Migliorini; Giulia Ranzanici; Eliana Marinari; Valérie Widmer; Johannes Alexander Lobrinus; Shahan Momjian; Joseph Costello; Paul R Walker; Hideho Okada; Toni Weinschenk; Christel Herold-Mende; Pierre-Yves Dietrich
Journal:  Oncoimmunology       Date:  2017-11-07       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.